News Releases

May 12, 2022
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on
May 10, 2022
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class small molecule kinase inhibitors for genetically defined oncology indications and rare diseases Ended
May 6, 2022
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the LifeSci
April 11, 2022
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors  Building a pipeline of multiple small molecule inhibitors targeting genetically defined diseases, including next generation
March 29, 2022
Cogent Biosciences to Host Virtual R&D Investor Event
CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced details for its planned Virtual R&D Investor Event on Friday, April 8,
March 15, 2022
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for April 8, 2022 Ended 2021 with $219.7 million in cash, sufficient to fund operations into 2024 CAMBRIDGE, Mass.
March 8, 2022
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming poster presentations
February 9, 2022
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. and BOULDER, Colo. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins , Chief Executive Officer and President, will
January 5, 2022
Cogent Biosciences Provides 2022 Corporate Guidance
APEX, SUMMIT and PEAK bezuclastinib clinical trials all initiated and enrolling APEX preliminary clinical data readout expected in the first half of 2022 R&D investor event planned April 2022 to detail robust discovery pipeline CAMBRIDGE, Mass. and BOULDER, Colo. , Jan.
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.